These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 19169683)

  • 1. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
    Ramanathan RK; Belani CP; Singh DA; Tanaka M; Lenz HJ; Yen Y; Kindler HL; Iqbal S; Longmate J; Mack PC; Lurje G; Gandour-Edwards R; Dancey J; Gandara DR
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):777-83. PubMed ID: 19169683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.
    Ravaud A; Hawkins R; Gardner JP; von der Maase H; Zantl N; Harper P; Rolland F; Audhuy B; Machiels JP; Pétavy F; Gore M; Schöffski P; El-Hariry I
    J Clin Oncol; 2008 May; 26(14):2285-91. PubMed ID: 18467719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.
    Peck J; Wei L; Zalupski M; O'Neil B; Villalona Calero M; Bekaii-Saab T
    Oncology; 2012; 82(3):175-9. PubMed ID: 22433475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
    Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C
    J Clin Oncol; 2005 Sep; 23(27):6657-63. PubMed ID: 16170173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.
    Wülfing C; Machiels JP; Richel DJ; Grimm MO; Treiber U; De Groot MR; Beuzeboc P; Parikh R; Pétavy F; El-Hariry IA
    Cancer; 2009 Jul; 115(13):2881-90. PubMed ID: 19399906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
    Thomas MB; Chadha R; Glover K; Wang X; Morris J; Brown T; Rashid A; Dancey J; Abbruzzese JL
    Cancer; 2007 Sep; 110(5):1059-67. PubMed ID: 17623837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
    Yen Y; Lim DW; Chung V; Morgan RJ; Leong LA; Shibata SI; Wagman LD; Marx H; Chu PG; Longmate JA; Lenz HJ; Ramanathan RK; Belani CP; Gandara DR
    Am J Clin Oncol; 2008 Aug; 31(4):317-22. PubMed ID: 18845988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
    Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT
    J Clin Oncol; 2007 Jul; 25(21):3069-75. PubMed ID: 17634485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
    Park JW; Finn RS; Kim JS; Karwal M; Li RK; Ismail F; Thomas M; Harris R; Baudelet C; Walters I; Raoul JL
    Clin Cancer Res; 2011 Apr; 17(7):1973-83. PubMed ID: 21349999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
    Rimassa L; Santoro A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
    Vora SR; Zheng H; Stadler ZK; Fuchs CS; Zhu AX
    Oncologist; 2009 Jul; 14(7):717-25. PubMed ID: 19581525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
    Zender L; Kubicka S
    Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
    Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
    Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
    J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
    Harrington KJ; El-Hariry IA; Holford CS; Lusinchi A; Nutting CM; Rosine D; Tanay M; Deutsch E; Matthews J; D'Ambrosio C; Turner SJ; Pandeshwara JS; Bourhis J
    J Clin Oncol; 2009 Mar; 27(7):1100-7. PubMed ID: 19171712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
    Bekaii-Saab T; Markowitz J; Prescott N; Sadee W; Heerema N; Wei L; Dai Z; Papp A; Campbell A; Culler K; Balint C; O'Neil B; Lee RM; Zalupski M; Dancey J; Chen H; Grever M; Eng C; Villalona-Calero M
    Clin Cancer Res; 2009 Sep; 15(18):5895-901. PubMed ID: 19737952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth factors as therapeutic targets in HCC.
    Furuse J
    Crit Rev Oncol Hematol; 2008 Jul; 67(1):8-15. PubMed ID: 18434184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.